Legal Press releases

Stockholm, March 9, 2022 - The European Medicines Agency has today, after reviewing stability data, approved the extension of the shelf life of the antigens in Strangvac to 28 months.

Stockholm, February 16, 2022 - Intervacc AB (publ) announces that the Company’s application for a Permit for Sale and Distribution of Strangvac^® in the U.S. has been submitted to the U.S. Department of ... Read more

Stockholm, February 1, 2022 - The European patent for Strangvac^®, a vaccine against equine strangles, is approved and in force until May 2031. Pending the approval of the supplementary protection ... Read more

Stockholm, January 21, 2022 - In the largest study of its kind, published in the 'Equine Veterinary Journal', scientists confirm that the antigens used in the Strangvac vaccine were highly conserved regardless of which ... Read more

Stockholm, December 17, 2021 - Due to the large and volatile trading in the company's share based on speculations on social media, Intervacc wants to clarify that Strangvac is centrally approved by EMA for sales ... Read more